Fibroblast activation protein (FAP) is upregulated in myelomatous bone and supports myeloma cell survival.
about
Fibroblast activation protein α in tumor microenvironment: recent progression and implications (review)Using substrate specificity of antiplasmin-cleaving enzyme for fibroblast activation protein inhibitor design.Advances in the understanding of myeloma bone disease and tumour growth.Clinical Implications of Marker Expression of Carcinoma-Associated Fibroblasts (CAFs) in Patients with Epithelial Ovarian Carcinoma After Treatment with Neoadjuvant Chemotherapy.Therapeutic effects of intrabone and systemic mesenchymal stem cell cytotherapy on myeloma bone disease and tumor growthTargeting inhibition of fibroblast activation protein-α and prolyl oligopeptidase activities on cells common to metastatic tumor microenvironmentsRole of decorin in the antimyeloma effects of osteoblasts.Advances in immunotherapy of multiple myeloma: from the discovery of tumor-associated antigens to clinical trials.The molecular characterization and clinical management of multiple myeloma in the post-genome era.The proteasome inhibitor, bortezomib suppresses primary myeloma and stimulates bone formation in myelomatous and nonmyelomatous bones in vivo.Mechanisms of multiple myeloma bone disease.Inhibitor of DASH proteases affects expression of adhesion molecules in osteoclasts and reduces myeloma growth and bone disease.Establishment and exploitation of hyperdiploid and non-hyperdiploid human myeloma cell lines.Atacicept (TACI-Ig) inhibits growth of TACI(high) primary myeloma cells in SCID-hu mice and in coculture with osteoclasts.Expression of anti-VEGF antibody together with anti-EGFR or anti-FAP enhances tumor regression as a result of vaccinia virotherapy.Up-regulation of hexokinaseII in myeloma cells: targeting myeloma cells with 3-bromopyruvate.Unique anti-myeloma activity by thiazolidine-2,4-dione compounds with Pim inhibiting activity.Targeting myeloma-osteoclast interaction with Vγ9Vδ2 T cells.Pinch-1 was up-regulated in leukemia BMSC and its possible effect.Hepatocyte growth factor pathway upregulation in the bone marrow microenvironment in multiple myeloma is associated with lytic bone disease.Myeloma bone disease: Pathophysiology and management.CD26 is a potential therapeutic target by humanized monoclonal antibody for the treatment of multiple myeloma
P2860
Q28082504-39969D32-95F9-4A87-BBB9-8302296AE218Q33436374-78786A20-242F-408A-8E68-5C3444F81DDBQ33829022-B51154D6-A9E5-4341-B20D-4EBC1A13A8DAQ34115941-03797C15-F58A-4FA7-8BAA-05D5E37CA024Q36092153-58E647B7-374D-4193-8F69-A840EEB9C2A1Q36730567-1CE2AFEC-A5FF-46E6-B8F8-E2DB0C4CD91BQ36732801-82F27466-D691-494C-9491-482D24E5ADAEQ36844954-BE546F77-16D9-46D3-A745-F4A61390265EQ36939043-D40B9076-2DC8-4FAA-851E-1FE6FC5A5262Q37034189-21C2B7F3-5D69-4FD5-B032-9909E76F200BQ37056408-1982D819-E117-440F-AB23-5DEABBC4E3FCQ37357828-17FB1478-AB7A-4FC8-B559-5C9A57145573Q37357836-D71A18B8-8B19-40F3-AF23-372D398ABE7DQ37407676-F5B84D61-658F-4C29-95D7-7C5DA8C424F4Q38845254-0F1BAB7C-970D-49E8-8858-DEFBACA34A12Q39402922-0B830EAD-A7A5-4092-B8E2-3EE7B72FF831Q47554666-372C0846-D2DD-4623-96B7-7726D315B9B1Q53238656-A1D965F6-8893-4082-AC1E-1A69064097FEQ54325441-BF9507E3-60AB-49F1-82CA-51B120F7254FQ54448123-533AB650-B66B-4A55-9BF5-9D5ED312BD2BQ55209965-B1069B55-B416-486A-B823-B1504DD0974FQ57801281-E68EB81A-8B8B-4FF5-8105-9A316239906A
P2860
Fibroblast activation protein (FAP) is upregulated in myelomatous bone and supports myeloma cell survival.
description
2006 nî lūn-bûn
@nan
2006年の論文
@ja
2006年学术文章
@wuu
2006年学术文章
@zh
2006年学术文章
@zh-cn
2006年学术文章
@zh-hans
2006年学术文章
@zh-my
2006年学术文章
@zh-sg
2006年學術文章
@yue
2006年學術文章
@zh-hant
name
Fibroblast activation protein ...... upports myeloma cell survival.
@en
Fibroblast activation protein
@nl
type
label
Fibroblast activation protein ...... upports myeloma cell survival.
@en
Fibroblast activation protein
@nl
prefLabel
Fibroblast activation protein ...... upports myeloma cell survival.
@en
Fibroblast activation protein
@nl
P2093
P2860
P1476
Fibroblast activation protein ...... upports myeloma cell survival.
@en
P2093
Fenghuang Zhan
John Shaughnessy
Joshua Epstein
P2860
P356
10.1111/J.1365-2141.2006.05976.X
P407
P577
2006-04-01T00:00:00Z